Previous 10 | Next 10 |
2024-03-13 08:50:11 ET Read the full article on Seeking Alpha For further details see: Cybin launches $150M oversubscribed private placement
2024-03-13 07:29:10 ET DENVER, Colo., Mar 13, 2024 ( 247marketnews.com )- Cybin Inc. (NYSE: CYBN ) announced, this morning, that the FDA granted Breakthrough Therapy Designation to CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Ma...
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ...
2024-03-13 06:55:38 ET More on Cybin De-Risking Psychedelics: Compass Pathways, Cybin And Atai Psychedelic stocks gain after FDA priority review for MDMA therapy Cybin reports Japan grant of additional patents for anxiety disorder treatment Seeking Alpha ...
- Breakthrough Therapy Designation (“BTD”) provides an expedited review pathway, as well as increased access to U.S. Food and Drug Administration (“FDA”) guidance on trial design, with the potential to significantly reduce drug development timelines - - First k...
- Program update includes 4-month durability data from Phase 2 trial of CYB003 in Major Depressive Disorder (“MDD”) - - Company speakers include Doug Drysdale, Chief Executive Officer and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer - Cybin Inc. ...
2024-03-07 11:29:12 ET More on Clearmind Medicine, Bright Minds, etc. Mind Medicine (MindMed) Inc. (MNMD) Q4 2023 Earnings Call Transcript Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts De-Risking Psychedelics: Compass Pathways, Cybin And Atai ...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be spotlighted at next month’s 44th annual TD Cowen Health Care Conference. The...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic treatment options, today announced unaudited financial results for its third quarter ended Dec. 31,...
News, Short Squeeze, Breakout and More Instantly...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting “a swell” of insider purchases followi...
Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update on progress made in fiscal 2024 ending on March 31st. In its presser , Cybin highlighted k...